Mallinckrodt Puts Down $1.3B To Acquire Cadence
Mark Trudeau, CEO and president of Mallinckrodt, said that the purchase of Cadence will help the company achieve the continued growth it desires.
"The acquisition of Cadence Pharmaceuticals is consistent with our goal of becoming a leading global specialty pharmaceuticals company," Trudeau said in a statement. "Ofirmev's growth is driven by an...
To view the full article, register now.